Patients with hypertension usually report lower healthrelated quality of life (HRQoL), but it is unclear whether this is secondary to high blood pressure (BP) per se, drug treatment or awareness of disease. In a crosssectional study using a multistage population-based sample, participants were interviewed and examined at home. Hypertension was defined by BP X140/90 mm Hg or use of BP-lowering drugs. HRQoL was assessed through the Short-Form Health Survey (SF-12) and presented as the physical component summary (PCS), mental component summary (MCS) and the SF-12 eightdomain scale. In total, 1858 individuals were evaluated, being 60.1% women, aged 52.5 ± 4.1 years old, and 39.9% men, aged 47.2±9.1 years old. Prevalence of hypertension was 34.2% (95% CI 31.5-36.9). The PCS scores for hypertensive and normotensive participants were 49.4 (CI 48.6-50.2) and 51.06 (CI 50.4-51.7) (P ¼ 0.01), respectively, and the MCS scores were 49.1 (CI 47.9-50.3) and 50.5 (CI 49.6-51.2) (P ¼ 0.06), respectively. Participants with hypertension and not using BP drugs had higher HRQoL scores (PCS 49.6; MCS 51.9) than those using BP drugs either with uncontrolled (PCS 45.3; MCS 49.4) or controlled BP (PCS 46.2; MCS 47.7; Po0.05). We concluded that individuals with hypertension have worse quality of life, particularly when their BP is controlled by drugs. This perception may lead to lower rates of adherence to treatment.
Introduction
Hypertension progresses with mild or no symptoms for many years until it is diagnosed or consequences of end-organ damage emerge. 1 At the moment of the diagnosis, physicians may well assume that the patient will share their optimistic view about the benefit of such diagnosis in face of the existence of many efficacious medical therapies and the usual good prognosis of patients under treatment. Nonetheless, quality of life is a subjective concept that depends on perception and individual preferences. [2] [3] [4] Disease labels and treatment lead to changes in lifestyle that may also affect healthrelated quality of life (HRQoL) and influence the adherence to treatment, a major issue nowadays for the treatment of hypertension and other chronic diseases. 5 Studies have mostly shown worst quality of life of patients with hypertension, [5] [6] [7] [8] [9] [10] but other studies contradict these findings. 11, 12 A systematic review of 20 original contributions identified lower quality of life among hypertensive individuals in most but not all studies. 13 Studies that could be included in a meta-analysis, and that had HRQoL evaluated by The Short-Form Health Survey (SF)-36 À or its reduced version SF-12 À , identified lower scores among individuals with hypertension or that reported to be hypertensive. 13 The studies were very heterogeneous with regard to selection criteria and comparison groups, limiting their external validity. Moreover, some aspects on the relationship between high blood pressure (BP) and quality of life are still unsolved. Among them are the influence of awareness of hypertension versus high BP itself, the influence of drug treatment in real conditions of use, the influence of control of BP, and the association with different domains and components of quality of life. The association between hypertension and quality of life, with particular attention to these aspects, was investigated in this population-based study.
Methods
This study is within the framework of the SOFT study (Syndrome of Obesity and Risk Factors for Cardiovascular Disease), a cross-sectional study that investigated individuals aged 18-90 years who were living in Porto Alegre, which is a State capital in Brazil with more than 1.5 million inhabitants and a health-development index of 0.800. Details of this survey were presented elsewhere.
14 Participants were selected by multistage population-based sampling on the basis of geographic subdivisions of the city, which were defined by the Brazilian Institute of Geography and Statistics. Supervisors established the age strata of the individuals in each household for further interview. Among adults 18-59 years of age, the sampling was proportional to the number of individuals, and all participants in the 60-90-year range were sampled.
The sample size needed to detect a difference of 10 points in the SF-12 s score between hypertensive and non-hypertensive individuals with a ratio of 1:3, a confidence interval of 95% and power of 80% was estimated at 1858 adult participants for HRQoL analyses.
Data were collected through a structured questionnaire administered during household interviews. The questionnaire included questions about the following: demographics; diet; physical activity; lifestyle habits, such as smoking and alcohol consumption; diseases; medication use; and previous medical history of hypertension.
Four standardized BP measurements were obtained over the course of the interview using an OMRON CP-705 (OMRON, Dupont, France) digital sphygmomanometer, according to technical recommendations. 15 Hypertension was defined as a BP of 140/ 90 mm Hg or higher, averaged over the four measurements; hypertension was also indicated by the use of BP-lowering drugs. 15 The SF-12, which is derived from the SF-36, [16] [17] [18] was used to assess HRQoL. The SF-12 is a generic multidimensional instrument for assessing HRQoL that consists of two components of 12 items, each of which is subdivided into subscales. The physical component (PCS; physical component summary) includes physical functioning, physical role limitations, bodily pain and general health; the mental component (MCS; mental component summary) refers to mental health, emotional role limitations, social functioning and vitality. The final score ranges from 0 (worst overall health state) to 100 (best health state). 18 This instrument was adapted and validated for the Portuguese language in a study applied to patients with rheumatoid arthritis. 19, 20 HRQoL of the study population was presented by score values ranging between 0 and 100 in the component summary (PCS and MCS) scores and the SF-12 eight-domain scale. The assessment of HRQoL by the SF-12 has become standard in epidemiological surveys because it is a generic instrument for assessing HRQoL and not just quality of life in general. 21 Moreover, because of its short length, its application is easier, particularly in population-based studies.
Data were entered into the Epi Info software database (Epi Info, Atlanta, GA, USA, version 2000) and checked for consistency of data entry by double entry. The scores of quality of life were standardized for the 1998 US population, as recommended by the SF-12 scoring manual. 16 Statistical analysis was performed in the complex samples option of the Statistical Program for Social Sciences version 16.0 (SPSS Inc., Chicago, IL, USA). At each sampling frame, a probability of selection was calculated to conduct the analysis, taking into account the effect of design. Crude analysis was performed using Pearson's w 2 -test (categorical variables) and t-test (continuous variables). Data were stratified or adjusted by gender, considering the gender differences in quality of life reported by several investigators. [19] [20] [21] Multivariate analysis was performed in the Complex Samples General Linear Model, including age, education and gender as covariates.
The study was approved by the Institutional Review Board of the Hospital de Clínicas de Porto Alegre, which is accredited by the Office of Human Research Protections, and all participants signed the informed consent form.
Results
In total, 1858 individuals were evaluated. The ages ranged from 18 to 96 years; 1117 (60.1%) were women aged 52.5 ± 4.1 years old and 741 (39.9%) were men aged 47.2 ± 9.1 years old. Table 1 shows the population characteristics and HRQoL scores by gender. Men had higher education and smoked and abused alcohol more frequently. Women were more frequently separated or widowed than men, and the women were generally older than the men. The HRQoL general population scores were 49.6 ( ± 9.8) for PCS and 50.2 ( ± 11.1) for MCS. Men had summary PCS and MCS scores of 50.9 (±8.7) and 52.7 ( ± 9.9), respectively, versus 48.7 ( ± 10.3) and 48.5 ( ± 11.5), respectively, for women (Po0.001). Men had domain scores that were somewhat higher than those for women.
The prevalence of hypertension was 34.2% (95% CI 31.5-36.9). Table 2 shows that individuals with hypertension had lower scores for HRQoL in all domains than normotensive participants, and the differences were significant, with the exception of the MCS scores. In the analyses stratified by gender (Table 3) , the worst quality of life persisted for hypertensive men and women, but lost significance in some domains in men for physical functioning. Scores for women were lower than in men for all domains, independent of the diagnosis of hypertension. The lower quality of life of individuals with hypertension was independent of age and education. Figure 1 shows the component summary scores of HRQoL measured by the SF-12 and domain scores, comparing participants with normal BP with participants with hypertension (with and without controlled BP), stratified by gender. Lower scores on all components and domains were found among men with controlled hypertension when compared with normotensive individuals or those with uncontrolled hypertension. Among women, the overall pattern was similar, and only the general health state was not different in women with controlled and uncontrolled BP. Women had lower HRQoL scores in both components and all domains when compared with men. Table 4 shows the HRQoL scores differed significantly between participants with controlled and uncontrolled hypertension using or not using BP agents. Participants with BP equal to or higher than 140/90 mm Hg not using BP drugs (38.3% of all hypertensives) tended to have higher HRQoL scores in all components of the SF-12 compared with those with BP of 140/90 mm Hg or higher on antihypertensive drugs (28.3% of all hypertensives) or BP lower than 140/90 mm Hg using antihypertensive drugs (33.4% of hypertensives).
The most commonly used antihypertensive drugs were diuretics (n ¼ 234, 12.3% of all participants with hypertension) and angiotensin-converting enzyme inhibitors (n ¼ 220, 11.8%). Monotherapy was more frequently employed than the association of drugs (42%), and the drug in these cases was an angiotensin-converting enzyme inhibitor. There was a tendency toward lower HRQoL in the PCS (Po0.09) scores of patients using an increasing number of antihypertensive drugs (1, 2, 3, 4 or more BP agents), whereas in the MCS, this difference was not significant. This means that patients who take a higher number of antihypertensive drugs have lower HRQoL in the PCS.
Discussion
In this population-based survey, we identified a high prevalence of hypertension (34.2%), which Health-related quality of life and hypertension DJ Trevisol et al was higher than the prevalence of 29.8% reported for this population more than 15 years ago. 22 Ageing of the population and increased prevalence of risk factors, particularly obesity, may explain this increase in the prevalence rate. HRQoL in this population evaluated by the eight SF domains and summary component scores (around 50) were similar to those of population-based studies conducted in different countries. 18 Compared with normotensive participants, hypertensive men and women had lower scores in PCS and MCS components. The differences for MCS in men were marginally significant. Quality of life in all domains and summary component scores of SF-12 were also lower in hypertensive compared with normotensive individuals; these findings are similar to those reported in other population-based surveys and in studies performed in outpatient clinics and hospitals. [6] [7] [8] [9] [10] [11] [12] 23 High diastolic BP (X110 mm Hg) and the presence of target-organ damage were also associated with lower scores of HRQoL in the domains of bodily pain, vitality and general health among patients with hypertension. 24 There is less association of hypertension with low quality of life than there is with other conditions, such as arthritis, diabetes, depression, congestive heart failure, lung disease and coronary heart disease. 25, 26 Lower HRQoL in women versus men has been reported in the general population and among normotensive and hypertensive individuals, 25, 27, 28 and this trend was also observed in our study. Some differences in the HRQoL scores lost significance in the stratified analyses but maintained the same trend both for men and women. Lower quality of life in women compared with men has been attributed to (among other factors) depression, hormonal changes and self perception of health. [29] [30] [31] The influence of treatment of hypertension on quality of life has been scarcely investigated in population-based surveys. 12 We determined that quality of life was lower in participants with controlled hypertension under drug treatment than in participants with uncontrolled hypertension using or not using BP drugs. These findings are discordant with those reported by Li et al., 32 who found higher HRQoL in controlled hypertensive patients compared with uncontrolled hypertensive patients under drug treatment. Another study showed that awareness of being hypertensive was associated with worse HRQoL. 32 On the other hand, Erickson and associates reported lower HRQoL due to symptoms associated with drug treatment. 23 The worst quality of life of treated hypertensive individuals with controlled BP could be attributed to the more intensive treatment to control BP levels and maintenance of lifestyle changes that could adversely influence HRQoL.
The association of drug treatment with lower quality of life has not been attributed to adverse effects of BP-lowering drugs as a whole or to a particular group of agents. The TOHMS trial, 33 which followed more than 1000 individuals randomized to four classes of blood agents and placebo for four years, did not find any difference in several scores of quality of life between participants who received active drugs or placebo. The low incidence of adverse effects of BP agents has been consistent in controlled clinical trials. Adverse events have been frequently attributed to BP drugs, but real adverse effects have been relatively uncommon in clinical trials. For instance, in the SHEP trial, 91.8% of the participants treated with chlorthalidone reported a complaint related to treatment, in comparison with 86.4% in participants treated who received placebo, showing that not more than 5% of the complaints were due to real adverse effects. 34 Conversely, adverse events, that is, intolerance to drugs ascribed to the nocebo effect, are quite frequent in clinical settings, where about 35% of patients under drug treatment reported an adverse event related to the drug. 35 Awareness of being sick and not the disease itself can be another reason for lower quality of life. In the SOFT study, we identified an association between the awareness of having hypertension, but not due to high BP, with higher scores of stress. 36 Other studies have reported lower HRQoL among people who consider themselves ill and take medication often. 6, 37 It is commonly accepted that some symptoms, such as headache, are caused by high BP, which could be another reason for feeling ill after being aware of the diagnosis of hypertension. In population-based surveys and in the clinical setting, we and others have shown that there is no association between high BP and headache, 38, 39 even for severe hypertension. 40 In addition, higher BP has been associated with lower perception of pain. 41 These findings suggest that the association between hypertension, and particularly of treated hypertension, with lower quality of life may be attributed to the awareness of disease and adverse events related to the use of BP agents and not to higher BP per se. The occurrence of end-organ damage finally lowers the quality of life. [41] [42] [43] The fact that patients with hypertension on drug treatment, particularly with controlled BP, present lower quality of life than their counterparts has important clinical implication, as the interruption of treatment could improve quality of life at the expense of increasing of BP. Physicians and patients should be aware about this possibility in order to maintain adherence to treatment. Longitudinal studies are necessary to confirm these findings.
Our study has some limitations that deserve attention. The cross-sectional design does not allow us to demonstrate a temporal association, but it is unlikely that poor quality of life is a cause of Health-related quality of life and hypertension DJ Trevisol et al hypertension or particularly of controlled hypertension. The MINICHAL questionnaire was specifically developed to investigate HRQoL among individuals with hypertension, 42 but was not available at the time of our data collection. Nevertheless, the SF-12 has been considered a powerful instrument to assess HRQoL. 43, 44 A further limitation of the study was that it did not determine whether those not on treatment were unaware of their hypertensive status. Presumably, some were identified by the study, others were aware that their BP was high but not yet started on treatment, and others were previously treated but non-compliant. This would have helped unpick the relationship between awareness of the diagnosis and HRQoL. The use of this questionnaire and the meticulous evaluation of the risk factors for hypertension, in a large sample of adults representative of a whole city, are strengths of our investigation.
In conclusion, individuals with hypertension have lower quality of life than normotensive participants, particularly when BP is controlled by drug treatment. Awareness of being sick and adverse events attributed to BP agents may be responsible for this association and not high BP per se.
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What is known about this topic K Patients with hypertension have lower health-related quality of life, but it is unclear whether this is secondary to high blood pressure per se, drug treatment or awareness of disease.
What this study adds K The worse quality of life of individuals with hypertension is more evident in patients under treatment, particularly when their blood pressure is controlled by drugs.
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